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Abstract 
Background: Previous studies have suggested that antithrombin may be beneficial for treating coagulopathy 
in patients with severe burns. However, robust evidence for this idea is lacking. We examined the hypothesis that 
antithrombin may be effective in treating patients with severe burns.
Methods: We performed propensity score-matched analyses of the nationwide administrative Japanese Diag-
nosis Procedure Combination inpatient database. We identified patients with severe burns (burn index ≥ 10) who 
were recorded in the database from 1 July 2010 to 31 March 2013. We compared patients who were administered 
antithrombin within 2 days of admission (antithrombin group) and those who were not administered antithrombin 
(control group). The main outcomes were 28-day mortality and ventilator-free days (VFDs).
Results: Eligible patients (n = 3223) from 618 hospitals were categorized into either an antithrombin group 
(n = 152) or control group (n = 3071). Propensity score matching created a matched cohort of 103 pairs with and 
without antithrombin. Twenty-eight-day mortality was lower in the antithrombin group compared with the control 
group in propensity-matched analysis (control vs. antithrombin, 47.6 vs. 33.0%; difference, 14.6%; 95% confidence 
interval [CI] 1.2–28.0). Cox regression analysis showed a significant difference in 28-day in-hospital mortality between 
the control and antithrombin propensity-matched groups (hazard ratio 0.58; 95% CI 0.37–0.90). There were signifi-
cantly more VFDs in the antithrombin compared with the control group in propensity score-matched analysis (control 
vs. antithrombin, 12.6 vs. 16.4 days; difference −3.7; 95% CI −7.2 to −0.12).
Conclusions: This nationwide database study demonstrated that antithrombin use may improve 28-day survival and 
increase VFDs in patients with severe burns. Further prospective studies are required to confirm these results.
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Background
Burns severe enough to require medical attention are 
observed in nearly 11 million people and represent 
the fourth most common type of injury globally [1]. 
Although most burns are not fatal, more than 300,000 
people worldwide do die each year of burn injuries [1]. 
The occurrence of coagulopathy in severe burns has been 
demonstrated in several studies [2–4]. Patients with 
severe burns are at high risk of inflammation and acti-
vation of the coagulation system, and a significant pro-
portion of patients present with coagulopathy unrelated 
to fluid administration [5]. The emergence of coagu-
lopathy is an independent predictor of 28-day mortality 
in patients with severe burns [2, 3, 5]. However, there is 
limited evidence regarding effective treatments for coag-
ulopathy in severe-burn patients, and clear treatment 
recommendations in these patients are lacking [4].
Several previous studies suggested that antithrombin 
administration may be effective for treating coagulopathy 
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in severe burns; however, there is currently no robust evi-
dence to support this idea [6–12]. Low antithrombin lev-
els have been identified as an independent predictor of 
mortality and duration of hospital stay [13]. Furthermore, 
a recent study reported therapeutic effects of antithrom-
bin substitution on myocardial dysfunction and inflam-
mation, as well as systemic fluid accumulation, following 
burns and smoke-inhalation injury in a clinically relevant 
animal model [8]. Lavrentieva et al. [9] conducted a pilot 
study (n  =  31) to evaluate the efficacy of antithrom-
bin in acute-phase burn-injury patients and found that 
antithrombin reduced hypercoagulation and improved 
organ function. However, the effect of antithrombin on 
mortality in patients with severe burns remains unknown.
We hypothesized that antithrombin could be effective 
for the treatment of patients with severe burns. The cur-
rent study aimed to evaluate this hypothesis using data 
from a large nationwide inpatient database in Japan.
Methods
Ethical statement
This study was approved by the Institutional Review 
Board of the University of Tokyo, which waived the 
requirement for informed patient consent because of the 
anonymous nature of the data.
Data source and variables
We analysed data from the Japanese Diagnosis Procedure 
Combination (DPC) database, the details of which have 
been described previously [14]. Briefly, the DPC database 
includes administrative claims and discharge abstract 
data for all inpatients discharged from over 1000 partici-
pating hospitals. It covers approximately 92% (244/266) 
of all tertiary-care emergency hospitals in Japan and 90% 
(90/100) of institutions certified for training burn spe-
cialists by the Japanese Society for Burn Injuries [15]. 
The database includes the following information for 
each patient: age; sex; primary diagnosis; comorbidities 
on admission and post-admission complications coded 
according to the International Classification of Dis-
eases, 10th revision codes (ICD-10) and written in Japa-
nese; medical procedures, including types of surgery, 
coded with original Japanese codes; daily records of drug 
administration and devices used; length of stay; and dis-
charge status. The dates of hospital admission, surgery, 
bedside procedures, drugs administered, and hospital 
discharge are recorded using a uniform data-submission 
format [14–18]. To optimize the accuracy of the recorded 
diagnoses, the responsible physicians are obliged to 
record the diagnoses with reference to medical charts. 
The diagnostic records are also linked to the payment 
system, and the attending physicians are required to 
report objective evidence for the diagnosis of the disease 
for reimbursement of treatment [14–18]. Patient follow-
up thus begins on the day of admission and ends on the 
date of discharge, either to home, to another hospital, or 
as a result of death. We could not follow up patients after 
discharge from hospital because this information was not 
available in the database [14–18].
The database also provides important clinical scores, 
including burn index and Japan Coma Scale (JCS) scores. 
Although the percentage of total burn-surface area 
was not available in the database, the burn index was 
recorded. The burn index takes into consideration both 
the surface area and thickness of the burn area: burn 
index  =  full thickness of total burn-surface area  +  1/2 
partial thickness of total burn-surface area [15, 19]. Fur-
thermore, a previous large study suggested that burn 
index was a better predictor of mortality in burn patients 
than percentage of total body surface area [20]. The JCS 
correlates well with the Glasgow Coma Scale, and con-
sciousness scored at 100 points on the JCS is equivalent 
to a score of 6–9 on the Glasgow Coma Scale. We catego-
rized the JCS scores into four groups: 0 (alert); 1–3 (delir-
ium); 10–30 (somnolence); and 100–300 (coma) [15–17]. 
To quantify the extent of the comorbidities, the ICD-10 
code for each comorbidity was converted to a score, and 
the sum was used to calculate the Charlson Comorbidity 
Index (CCI), as described previously [15, 21, 22]. Briefly, 
the CCI provides a method of predicting mortality by 
classifying or weighting comorbidities and has been 
widely used by health researchers to measure case mixes 
and disease burdens [21]. We categorized hospital types 
as academic or non-academic. We defined hospital vol-
ume as the number of eligible patients treated in the cur-
rent study and categorized hospital volume into tertiles 
(low, medium, and high).
Patient selection and endpoints
We identified patients with severe burns (burn 
index ≥ 10) [15] who were recorded in the database from 
1 July 2010 to 31 March 2013. We compared patients 
who were administered antithrombin within 2  days of 
admission (antithrombin group) and those who were not 
administered antithrombin (control group). The exclu-
sion criteria for this study were: out-of-hospital car-
diac arrest, discharge within 2  days after admission (to 
avoid immortal time bias), and readmitted patients with 
burns (to avoid patients with planned operations). All 
the antithrombin used in the current study was plasma-
derived antithrombin. Recombinant antithrombin was 
not available in Japan during the study period, though 
recombinant antithrombin use was allowed in a limited 
number of hospitals from September 2015.
The primary endpoint of the study was all-cause 28-day 
in-hospital mortality. Ventilator-free days (VFDs) were 
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a secondary endpoint in the propensity score-matched 
groups [23]. VFDs were defined as the number of days 
the patient remained alive without mechanical ventila-
tion assistance during the first 28  days after admission; 
patients who died before day 28 were assigned 0  days 
[23]. We also evaluated incidence of post-admission 
complications including intracranial haemorrhage, gas-
trointestinal bleeding, thrombotic disorders (pulmonary 
embolism and deep venous thrombosis), and renal failure 
(acute renal failure and/or requirement of renal replace-
ment therapy).
Statistical analysis
We performed one-to-one matching analysis between 
the antithrombin and control groups, based on estimated 
propensity scores for each patient [24, 25]. We assessed 
the propensity score by fitting a logistic regression model 
for antithrombin use as a function of the patients’ demo-
graphic and clinical characteristics, and hospital factors, 
including the following, which were previously reported 
to have the potential to affect mortality and the extent of 
haemostatic changes in patients with severe burns: age; 
sex; burn index; CCI, level of consciousness on admis-
sion; hospital type and hospital volume; inhalation injury 
with/without requirement for mechanical ventilation; 
use of catecholamines (dobutamine, norepinephrine, 
and/or dopamine); treatment with albumin, haptoglobin, 
and other blood products; use of drugs for disseminated 
intravascular coagulation (heparin, thrombomodulin, 
gabexate mesilate, nafamostat mesilate, or ulinastatin); 
and requirement for escharotomy and debridement 
[1, 4, 5, 13, 15, 17, 19, 26–31]. The C-statistic for evalu-
ating the goodness-of-fit was calculated. One-to-one 
matched analysis using nearest-neighbour matching was 
performed based on the estimated propensity scores 
of the patients; a match was accepted when a patient in 
the antithrombin group had an estimated score within 
0.2 standard deviations of a patient in the control group 
[24]. We examined the balance in baseline variables using 
standardized differences, where an absolute value <10% 
was regarded as balanced [24]. Data are expressed as 
number (%) or mean (standard deviation). Continuous 
variables were compared between groups using t tests, 
and categorical variables were compared using χ2 test or 
Fisher’s exact tests. A value of P less than 0.05 was con-
sidered statistically significant. Cox regression analysis 
was used to assess differences in 28-day in-hospital mor-
tality between propensity score-matched patients with 
and without antithrombin treatment [24]. We performed 
logistic regression analysis fitted with generalized esti-
mating equations to examine the association between 
antithrombin use and 28-day survival accounting for the 
paired nature of the propensity score-matched patients 
[24]. Because of its retrospective nature, we did not per-
form sample-size estimation for the current study. All 
statistical analyses were performed using IBM SPSS ver-
sion 22 (IBM Corp., Armonk, NY, USA).
Results
Patients
A total of 3223 patients treated at 618 hospitals dur-
ing the 33-month study period were identified as eligi-
ble. Patients were divided into an antithrombin group 
(n =  152) and a control group (n =  3071), from which 
103 propensity score-matched pairs were generated 
(Fig. 1). The C-statistic indicated a goodness-of-fit of 0.95 
for the propensity score model.
Table  1 shows the baseline characteristics of the 
unmatched and propensity score-matched groups. 
Patients were more likely to receive antithrombin if they 
had severe burns, a higher burn index, and more require-
ments for mechanical ventilation, catecholamines, and 
other treatments, according to comparisons between 
unmatched groups. After propensity score matching, 
most of the baseline patient characteristics were well 
balanced between the groups. There was no significant 
difference in associated trauma lesions between the 
two groups (Additional file  1: Table  S1). The median 
dose of antithrombin administered in the antithrombin 
group was 1500 U/day (minimum 500 U/day, maximum 
3000 U/day; 90 percentiles 1500–3000 U/day) for 3 days 
(minimum 1  days, maximum 48  days; 90 percentiles 
2–17 days). The median length of hospital stay among eli-
gible patients was 54 days.
Endpoints
Overall 28-day mortality was 14.7% (475/3223) in this 
cohort. Twenty-eight-day mortality was higher in the 
antithrombin group compared with the control group in 
unmatched analysis (control vs. antithrombin, 13.5 vs. 
Fig. 1 Patient selection
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39.5%; difference −26.0%; 95% confidence interval [CI] 
−31.7 to −20.2), but 28-day mortality was lower in the 
antithrombin compared with the control group in pro-
pensity-matched analysis (control vs. antithrombin, 47.6 
vs. 33.0%; difference 14.6%; 95% CI 1.2–28.0) (Table  2). 
Cox regression analysis showed a significant difference 
in 28-day in-hospital mortality between the control and 
antithrombin propensity-matched groups (hazard ratio 
Table 1 Baseline patient characteristics in the unmatched and propensity score-matched groups
SD standard deviation
Variable Unmatched groups Matched groups








Age, years (SD) 56.2 (26.5) 62.7 (22.0) −27.0 63.6 (21.3) 61.6 (21.8) 9.2
Sex (male) 1887 (61.4) 97 (63.8) −4.9 66 (64.1) 68 (66.0) −4.1
Burn index, mean 
(SD)




188 (6.1) 1 (0.7) 30.5 1 (1.0) 1 (1.0) 0.0
Mechanical  
ventilation
651 (21.2) 124 (81.6) −151.6 83 (80.6) 79 (76.7) 9.5
Charlson Comor-
bidity Index ≥ 1
409 (13.3) 11 (7.2) 20.1 8 (7.8) 7 (6.8) 3.7
Academic hospital 1097 (35.7) 108 (71.1) −75.7 67 (65.0) 69 (67.0) −4.1
Hospital volume, cases
 Low 1163 (37.9) 14 (9.2) 71.8 13 (12.6) 12 (11.7) 3.0
 Medium 942 (30.7) 59 (38.8) −17.2 44 (42.7) 38 (36.9) 11.9
 High 966 (31.5) 79 (52.0) −42.5 46 (44.7) 53 (51.5) −13.6
Consciousness level 0.0
 Alert 2230 (72.6) 62 (40.8) 67.8 40 (38.8) 45 (43.7) −9.9
 Delirium 459 (14.9) 38 (25.0) −25.3 34 (33.0) 27 (26.2) 14.9
 Somnolence 129 (4.2) 15 (9.9) −22.3 9 (8.7) 11 (10.7) −6.6
 Coma 253 (8.2) 37 (24.3) −44.7 20 (19.4) 20 (19.4) 0.0
Antibiotics use 1229 (40.0) 114 (75.0) −75.7 76 (73.8) 74 (71.8) 4.4
Catecholamines
 Dopamine use 233 (7.6) 44 (28.9) −57.5 31 (30.1) 27 (26.2) 8.6
 Dobutamine use 47 (1.5) 13 (8.6) −32.5 6 (5.8) 9 (8.7) −11.2
 Noradrenaline use 139 (4.5) 28 (18.4) −44.7 15 (14.6) 14 (13.6) 2.8
Escharotomy  
performed
130 (4.2) 23 (15.1) −37.5 16 (15.5) 18 (17.5) −5.2
Debridement 
performed
127 (4.1) 10 (6.6) −10.9 7 (6.8) 6 (5.8) 4.0
Red blood cell use 109 (3.5) 39 (25.7) −65.9 23 (22.3) 21 (20.4) 4.7
Fresh-frozen plasma 
use
217 (7.1) 81 (53.3) −116.5 44 (42.7) 45 (43.7) −2.0
Platelet use 19 (0.6) 15 (9.9) −42.4 5 (4.9) 4 (3.9) 4.8
Albumin use 608 (19.8) 133 (87.5) −184.9 89 (86.4) 87 (84.5) 5.5
Haptoglobin use 196 (6.4) 67 (44.1) −96.3 31 (30.1) 31 (30.1) 0.0
Heparin use 644 (21.0) 110 (72.4) −120.2 73 (70.9) 72 (69.9) 2.1
Thrombomodulin 
use
14 (0.5) 30 (19.7) −67.5 4 (3.9) 5 (4.9) −4.8
Gabexate  
mesilate use
25 (0.8) 15 (9.9) −41.1 5 (4.9) 6 (5.8) −4.3
Nafamostat  
mesilate use
57 (1.9) 19 (12.5) −42.1 16 (15.5) 16 (15.5) 0.0
Ulinastatin use 50 (1.6) 20 (13.2) −45.2 9 (8.7) 11 (10.7) −6.6
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0.58; 95% CI 0.37–0.90) (Fig. 2). Logistic regression anal-
yses using generalized estimating equations accounting 
for the paired nature of the propensity score-matched 
patients showed a significant association between 
antithrombin use and 28-day mortality in the propensity-
matched groups (odds ratio 0.54; 95% CI 0.31–0.95).
There were significantly more VFDs in the antithrom-
bin group compared with the propensity score-
matched control group (control vs. antithrombin, 12.6 
vs. 16.4  days; difference −3.7; 95% CI −7.2 to −0.12) 
(Table 3). There was no significant difference in the inci-
dence of post-admission complications between patients 
with and without antithrombin in the matched groups.
Discussion
In the current study, we analysed data from a Japanese 
nationwide in-hospital database and found a significant 
association between antithrombin use and reduction in 
28-day mortality in patients with severe burns. This find-
ing was robust with regard to the results obtained by 
logistic regression and survival analyses. Antithrombin 
use was also associated with more VFDs in these patients.
The strengths of the current study included its use of 
a nationwide database and controlling for major factors 
(e.g. age, size and depth of the burn, and the existence 
of inhalation injury) that could potentially affect mor-
tality and the extent of haemostatic changes in patients. 
The extent of haemostatic change is associated with 
the severity of the burn [26]; although most patients 
with mild burns have no systemic coagulation changes, 
patients with severe burns frequently develop coagulopa-
thy [26]. We therefore only included patients with severe 
burns (i.e. burn index >10) [15] in the current study. In 
addition to burn size, full-thickness burns and inhala-
tion trauma are also associated with the occurrence and 
severity of systemic coagulopathy [5, 32]. The baseline 
patient characteristics in the unmatched groups sug-
gested that antithrombin use was higher in patients with 
severe burns (e.g. those with higher mortality and higher 
burn index and those requiring mechanical ventilation, 
catecholamines, and other treatments). However, we 
ensured the comparabilities of the two groups by propen-
sity score matching, which provides a sound method for 
constructing a randomized experiment-like situation by 
comparing groups with similar observed characteristics, 
without specifying the relationships between confound-
ers and outcomes [24]. We included factors that could 
Table 2 Comparisons of 28-day in-hospital mortality rates between the groups
Control Antithrombin Difference (95% CI) P value
Unmatched groups 13.5% (415/3071) 39.5% (60/152) −26.0% (−31.7 to −20.2) <0.001
Propensity-matched groups 47.6% (49/103) 33.0% (34/103) 14.7% (1.2 to 28.0) 0.03
Fig. 2 Survival plots for propensity-matched groups of patients 
treated with or without antithrombin. The survival rate was higher in 
the antithrombin group compared with the control group (hazard 
ratio 0.58; 95% CI 0.37–0.90)
Table 3 Secondary endpoints in unmatched and matched groups
Outcomes Unmatched groups Matched groups
Control (n = 3071) Antithrombin (n = 152) P value Control (n = 103) Antithrombin (n = 103) P value
Ventilator-free days 23.1 (10.0) 15.2 (13.2) <0.001 12.6 (12.9) 16.4 (12.8) 0.04
Post-admission complications
 Intracranial haemorrhage 9 (0.3) 2 (1.3) 0.09 0 (0) 0 (0) NA
 Gastrointestinal bleeding 19 (0.6) 0 (0) 1.0 2 (1.9) 0 (0) 0.50
 Thrombotic disorders 22 (0.7) 0 (0) 0.62 1 (1.0) 0 (0) 1.0
 Acute renal failure 116 (3.8) 26 (17.1) <0.001 13 (12.6) 18 (17.6) 0.43
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potentially affect mortality and the extent of haemostatic 
changes in patients with severe burns when estimating 
propensity scores, such as age, burn-surface area and 
depth (i.e. burn index), comorbidities, and mechanical 
ventilation status [15, 19, 28]. After one-to-one propen-
sity score matching, the two groups (i.e. antithrombin 
vs. control) were well balanced in most of the measured 
variables. Our results suggested that patients with severe 
burns who received antithrombin were less likely to die 
and had more VFDs than those who did not receive 
antithrombin. There was no significant difference in the 
incidence of post-admission complications between two 
groups. The current results were compatible with those 
of previous sepsis studies, which found that antithrombin 
did not increase bleeding risk, at least at the dose used in 
Japan (i.e. 1500 U/day) [33, 34].
Several previous studies suggested that severe thermal 
injury is associated with early activation of the coagula-
tion cascade and the emergence of coagulopathy, which 
worsens the outcome of burns patients [2–5]. Interest-
ingly, several similar patterns of procoagulant and anti-
fibrinolytic changes, as well as natural anticoagulant 
system impairments, were witnessed in both early-stage 
severe-burn patients and sepsis patients [2, 3, 9, 35]. The 
guidelines of the Japanese Society of Thrombosis Hae-
mostasis [36] and the Japanese Society of Intensive Care 
Medicine [37] both recommend the use of supplemental 
antithrombin in patients with sepsis-associated coagu-
lopathy, and anticoagulant therapy, including antithrom-
bin, is thus commonly used in clinical practice in Japan 
[34]. Although no large randomized trials have suggested 
the effectiveness of antithrombin use, recent nation-
wide database studies suggested an association between 
lower in-hospital mortality and supplemental antithrom-
bin administration among patients with pneumonia and 
abdominal sepsis [16, 29].
Several treatment guidelines for burns, including 
Japanese guidelines [38], do not address or recommend 
the use of anticoagulation treatments for severe-burn 
patients, because of a lack of scientific evidence [39]. 
European guidelines for bleeding care in trauma manage-
ment suggest that antithrombin is not recommended in 
acutely bleeding trauma patients because of the increased 
risk of bleeding events and its failure to reduce over-
all mortality [40]. Although numerous studies have 
explored coagulopathy in sepsis patients, few have evalu-
ated coagulopathy in severe-burn patients in any detail 
[4]. Moreover, clear definitions or diagnostic criteria for 
coagulopathy after burns are currently absent. A lack of 
simple and easy-to-interpret diagnostic tests may thus 
disguise the true incidence of coagulopathy in patients 
with severe burns [4]. Antithrombin deficiency is com-
mon after burns and is related to total burn-surface area 
and inhalation injury, increased mortality, and longer 
hospital stay [13]. However, treatments for coagulopathy 
after severe burns may be less popular than treatments 
for sepsis-associated coagulopathy. Indeed, the cur-
rent nationwide study, using data from a country where 
antithrombin is commonly used as anticoagulant therapy 
in clinical practice [34], found that antithrombin was only 
administered to 152 of 3223 eligible severe-burn patients. 
The current results may thus support further prospective 
studies in this area.
A previous study suggested that early-onset coagu-
lopathy was associated with prolonged mechanical ven-
tilation [32], while the current results indicated that 
antithrombin use was associated with more VFDs. This 
may be because antithrombin acts as an anticoagulant 
with anti-inflammatory properties. A previous observa-
tional study [41] showed that pulmonary coagulopathy 
seemed intrinsic to burn injuries and inhalation trauma, 
and concluded that patients with burn injuries and inha-
lation trauma requiring mechanical ventilation showed a 
distinct and sustained procoagulant and antifibrinolytic 
shift in the pulmonary compartment, indicating that 
pulmonary coagulopathy could be an important thera-
peutic target in these patients. Several recent experi-
mental studies suggested that antithrombin attenuates 
myocardial dysfunction and pulmonary vascular leakage 
in patients with severe burns and inhalation injury [8, 
42]. Rehberg et  al. [42] showed an interaction between 
antithrombin and neutrophils in vivo and demonstrated 
its pathophysiological role in vascular leakage and the 
therapeutic potential of antithrombin in a sheep model. 
Rehberg et  al. [8] also demonstrated therapeutic effects 
of antithrombin in terms of myocardial dysfunction and 
inflammation, as well as systemic fluid accumulation 
following burns and smoke-inhalation injury in a sheep 
model. Based on the current and previous studies [8, 41, 
42], supplemental antithrombin treatment may represent 
a valuable therapeutic approach for cardiovascular dys-
function and inflammation after burn and smoke-inha-
lation injury. However, further studies are required to 
confirm these results.
This study had some limitations. First, the current study 
was retrospective and observational in nature, without 
randomization. Even though propensity score matching 
was used to adjust for differences in baseline character-
istics and disease severity, including factors that could 
potentially affect mortality and the extent of haemostatic 
change in patients with severe burns, there may still have 
been bias in the form of unmeasured confounders. Pos-
sible confounding parameters include laboratory-based 
coagulation tests, which indicate the level of coagu-
lopathy (e.g. international normalized ratio, activated 
partial thromboplastin time, antithrombin), systemic 
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inflammatory syndrome response, disseminated intra-
vascular coagulation scoring system, blood gas analysis, 
serum lactate level, fluid balance per day, haemodilution 
caused by large amounts of resuscitation fluids together 
with hypothermia, and type of hospital admission (e.g. 
general burn ward or advanced burn unit). Unfortunately, 
these data were not available from the DPC database. 
However, previous studies suggested that the severity of 
coagulopathy was correlated with the extent and depth 
of the burn and the existence of inhalation injury [4, 26], 
and we were able to match these factors using propen-
sity scoring, when comparing the outcomes between 
the antithrombin and control groups. Second, this study 
only evaluated the association between early-phase 
antithrombin use and outcomes and did not evaluate the 
effect of later-phase antithrombin use (e.g. antithrom-
bin use after sepsis-associated disseminated intravascu-
lar coagulation due to burn-wound infection). Third, we 
could not identify the cause of death or long-term out-
come from the current DPC database and therefore could 
not speculate on the factors responsible for the improved 
28-day mortality in the antithrombin group compared 
with the control group. Fourth, we did not determine 
whether the replacement of coagulation factors using 
fresh-frozen plasma was superior to antithrombin provi-
sion, though this research question should be evaluated 
in future studies.
Conclusions
 Analysis of this nationwide database demonstrated that 
antithrombin use may improve 28-day survival in severe-
burn patients. However, further studies are required to 
confirm these results.
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